Change the content of the APO В with the development of experimental hyper-cholesterolemia and ways to correct it

Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/1400

Full metadata record

DC Field	Value	Language
dc.contributor.author	Azizova D.M., Sabirova R.A., Khalilova R.K.	-
dc.date.accessioned	2022-01-02T17:13:30Z	-
dc.date.available	2022-01-02T17:13:30Z	-
dc.date.issued	2019	-
dc.identifier.issn	2455-3301	-
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/1400	-
dc.description.abstract	The study examined the effect of Biomaysa on the content of apoprotein in and total cholesterol, lipoprotein cholesterol in the dynamics of experimental hypercholesterolemia. Apoprotein B. of combined administration Biomaysa and ultroksa installed significant difference in the reduction of total cholesterol levels in ApoB 2.2 and 1.5, indicating good cholesterol reducing the effectiveness of the combination of these drugs by activating LDL receptor capture.	en_US
dc.language.iso	en	en_US
dc.publisher	World Journal of Pharmaceutical and Medical Re-search.	en_US
dc.relation.ispartofseries	№ 5(6).;313-316	-
dc.subject	experimental hypercholesterolemia, blood, atherosclerosis, lipoproteins, cholesterol, apoprotein B.	en_US
dc.title	Change the content of the APO В with the development of experimental hyper-cholesterolemia and ways to correct it	en_US
dc.type	Article	en_US
Appears in Collections:	Thesis, Articles

Files in This Item:

File	Description	Size	Format
40 WJPMR 2749 (1) Индия.pdf		398.2 kB	Adobe PDF	View/Open

DSpace JSPUI